Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common phosphate supplements may skew a key hormone test, study asks

NCT ID NCT07827989

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Doctors often give phosphate supplements to hospitalized patients with low phosphate. This study asks whether those supplements cause a temporary rise in FGF23, a hormone that controls phosphate. Researchers will measure FGF23 and phosphate in blood samples from 60 adults in intensive care, oncology, or rheumatology. The goal is to learn if supplementation could make a non-FGF23-related phosphate problem look like an FGF23-related one.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
phosphate supplementation
What this could lead to
If phosphate supplements do raise FGF23, doctors may need to time blood tests differently to avoid misreading a patient's condition. This could make diagnosis of low-phosphate causes more accurate.
What could go wrong
This is a small observational study of 60 hospitalized patients, so it cannot prove cause and effect. Results may not apply to people outside intensive care, oncology, or rheumatology settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients hospitalized in adult intensive care, oncology, or rheumatology * Hypophosphatemia \< 0.8 mmol/L * Clinical indication for phosphate supplementation Exclusion Criteria: * Chronic kidney disease, stage ≥ 3 (eGFR \< 60 mL/min/1.73 m²) * Treatment with Ferinject® within the past year * Sepsis * Current treatment with active vitamin D * Pregnancy or breastfeeding * Inability to perform blood draws due to insufficient venous access * Weight \< 35 kg (for intensive care patients only) * Hypercalcemia \> 2.6 mmol/L

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Calcium-phosphorus metabolism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypophosphatemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Calcium-phosphorus metabolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Clermont-Ferrand Service Oncologie

    RECRUITING

    Clermont-Ferrand, France

  • CHU Clermont-Ferrand Service Rhumatologie

    RECRUITING

    Clermont-Ferrand, France

  • CHU Clermont-Ferrand Service de réanimation

    RECRUITING

    Clermont-Ferrand, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.